About V-type proton ATPase subunit C 2
V-type proton ATPase subunit C 2 (ATP6V1C2) is a protein
from Homo sapiens identified by UniProt accession
Q8NEY4, 427 residues long.
MolForge cross-references it against 0 known binders and
34 disease associations.
Target properties
| Protein name | V-type proton ATPase subunit C 2 |
| UniProt accession | Q8NEY4 |
| Gene | ATP6V1C2 |
| Organism | Homo sapiens |
| Length | 427 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (34)
Diseases linked to this target (Open Targets).
- distal renal tubular acidosis · score 0.26
- breast adenocarcinoma · score 0.21
- glioblastoma multiforme · score 0.14
- forced expiratory volume · score 0.13
- vital capacity · score 0.09
- mathematical ability · score 0.05
- self reported educational attainment · score 0.04
- esophageal squamous cell carcinoma · score 0.03
- clear cell renal carcinoma · score 0.03
- prostate carcinoma · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8NEY4-F1 | alphafold | PREDICTED | 85.64 | — |
Amino-acid sequence (427 residues)
MSEFWLISAP GDKENLQALE RMNTVTSKSN LSYNTKFAIP DFKVGTLDSL VGLSDELGKL DTFAESLIRR MAQSVVEVME DSKGKVQEHL LANGVDLTSF VTHFEWDMAK YPVKQPLVSV VDTIAKQLAQ IEMDLKSRTA AYNTLKTNLE NLEKKSMGNL FTRTLSDIVS KEDFVLDSEY LVTLLVIVPK PNYSQWQKTY ESLSDMVVPR STKLITEDKE GGLFTVTLFR KVIEDFKTKA KENKFTVREF YYDEKEIERE REEMARLLSD KKQQYQTSCV ALKKGSSTFP DHKVKVTPLG NPDRPAAGQT DRERESEGEG EGPLLRWLKV NFSEAFIAWI HIKALRVFVE SVLRYGLPVN FQAVLLQPHK KSSTKRLREV LNSVFRHLDE VAATSILDAS VEIPGLQLNN QDYFPYVYFH IDLSLLD
Explore V-type proton ATPase subunit C 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets